Table 1 S1 Studies in Advanced Gastric Cancer
Abstract/author | Study agents | Patient number | Study Design | RR | PFS | OS |
|---|---|---|---|---|---|---|
A4534/ Jeung et al. | S1, Docetaxel, Cisplatin | 80 | Randomized phase II Docetaxel + S1 or Docetaxel + cisplatin | 44% 24% | 198 days 143 days (p = 0.03) | NR |
A4533/ Jin et al. | S1 Cisplatin 5-FU | 230 | Randomized phase III S1 vs. S1 + cisplatin vs. 5-FU + cisplatin | 25% 38% 19% (p = 0.021) | 267 days 433 days 309 days (p = 0.008) | NR |
A4537/ Sato et al. | S1 Docetaxel Cisplatin | 31 | Phase II study | 87% | 7.7 months | 19 months |